Print Friendly, PDF & Email
The future of cancer therapy: the genome editing era @ Magna Graecia University - Campus S. Venuta - Aula Magna C, 1° Level, Building G
Giu 8–Giu 9 giorno intero
The future of cancer therapy: the genome editing era @ Magna Graecia University - Campus S. Venuta - Aula Magna C, 1° Level, Building G | Catanzaro | Calabria | Italia


In June 2017, the Italian Association for Cell Cultures (AICC) have  organized focused meeting dedicated to "Genome Editing". During the
meeting several national and international experts in the field will discuss
this interesting technical innovation and its possible applications in basic,
translational research and design of novel anti-cancer therapy. Genome
editing is a technology that induces specific changes in the DNA of a cell or
organism that allows studying their influence in the determination of the
phenotypic characteristics. The meeting aims to transfer to the participants
the know-how on the currently available methods to induce changes in the
DNA of a cell system and how to use them to accurately study the function
of different genes, to understand how they work and their definitive
biological effects. The meeting will also illustrate several cell and animal
models, and will end with a practical demonstration of advanced models for
the study of different human diseases in order to design innovative
therapeutic approaches. With these specific objectives, the meeting has
been approved by Italian Ministry of Health for Continuous Education and
Training in medical, biological, pharmaceutical and technological areas.
Maria Teresa Di Martino



8 June 2017

10.00 Registration

10.30 Introduction: PierosandroTagliaferri, Pierfrancesco Tassone
Greetings from the Chancellor and local authorities
Pre-meeting: “Hot topics in Medical Oncology:
From genomics to molecular therapies of human cancer”
Chairs: Vito Barbieri (Catanzaro, Italy) - Marco Rossi (Catanzaro, Italy)

11.00 PDL1 analysis and beyond in lung cancer immunotherapy
Umberto Malapelle (Naples, Italy)

11.20 New generation of kinase inhibitor in the continuum of care of thyroid and renal-cell cancer
Speaker to be announced

11.40 CDK inhibitors: a new perspectives in breast cancer
Enrico Ricevuto (L’Aquila, Italy)

12.00 Liquid Biopsy in novel cancer treatment scenario
Marta Castiglia (Palermo, Italy)

12.20 Genomics of ovarian cancer in predictive oncology: the PARP inhibitors case
Ettore Capoluongo (Rome, Italy)

12.40 Discussion and closing remarks

13.00 Light lunch*

14.00 Opening ceremony
Greeting from AICC President Katia Scotlandi (Bologna, Italy)
Welcome and Meeting introduction Maria Teresa Di Martino (Catanzaro, Italy)
Session 1: CRISPR-Cas9-based therapeutic strategies against human diseases
Chairs: Stefania Meschini (Rome, Italy) - Carlo Leonetti (Rome, Italy)

14.30 TALEN gene edited cells for Allogeneic Adoptive Immunotherapy: from clean room to off-the-shelf
Roman Galetto (Cellectis SA, France)

14.50 Genome editing of T lymphocytes for cancer immunotherapy
Chiara Bonini (Milan, Italy)

15.10 CRISPR/Cas9 mediated knock-out of RUNX2 in melanoma cells
Maria Teresa Valenti (Verona, Italy)

15.30 CRISPR/Cas9 rescue of gene dosage in patient-specific models of neurodevelopmental
disorders caused by large CNV
Giuseppe Testa (Milan, Italy)

15.50 Functional genomic in cancer research
Simona Lamba (Turin, Italy)

16.10 Coffee Break*

16.30 CRISPR/Cas9 system on zebrafish to generate human disease model
Gianluca Deflorian (Milan, Italy)

16.50 The use of CRISPR/Cas9 knock-out technology in non-mammalian animal models
Thomas Vaccari (Milan, Italy)

17.10 CRISPR Gene Editing: Resources for High-Throughput Screening and Disease Models
Livio Loffarelli (Thermo Scientific, Italy)

17.30 Novel Technologies For Rapid Generation Of Custom Animal Models And Streamlined
Cloning Workflows (NOT for ECM evaluation)
Matthew Wheeler, Kristofer Müssar (Cyagen Biosciences GmbH, Europe)
Close session and concluding remarks

9 June 2017

Session 2: Insights in Genome Editing Technologies
Chairs: Francesca Zazzeroni (L’Aquila, Italy) - Massimo Donadelli (Verona, Italy)

9.00 Construction of sgRNA-Cas9 complexes and identification of single-cell mutations to
determine editing frequency
Franco Martinez (EuroClone, Italy)

9.20 How to improve your CRISPR genome editing experiments
Mirko Vanetti (Integrated DNA Technologies, Italy)

9.40 Rapid and tunable method to temporally control gene editing based on conditional
Cas9 stabilization
Vincenzo Corbo (Verona, Italy)

10.00 CRISPR/Cas9 for the study of the interactions between viral and cellular proteins
Donato Zipeto (Verona, Italy)

10.20 Targeted Genome Editing using CRISPR Technology (NOT for ECM evaluation)
Silvia Di Meglio (Merck Sigma-Aldrich srl, Italy)
Close session and concluding remarks

10.40 Coffee Break*

Session 3: CRISPR-Cas9 perspectives in genome editing
Chairs: Marcello Maggiolini (Cosenza, Italy) - Michele Caraglia (Naples, Italy)

11.00 A non-integrative strategy to streamline the derivation of isogenic iPSC lines through
the Cas9/sgRNAribonucleoproteic complex
Sebastiano Trattaro (Milan, Italy)

11.20 Epigenome deregulation and mining in leukemias
Lucia Altucci (Naples, Italy)

11.40 Genome editing in human repopulating hematopoietic stem cells
Pietro Genovese (Milan, Italy)

12.00 Genome editing and generation of physiologically relevant model of leukemogenesis
Giovanni Morrone (Catanzaro, Italy)

12.20 High efficiency Genome Editing using EnGenCRISPR/Cas9 Ribonucleoprotein Complexes
(NOT for ECM evaluation)
Karl Von Laer (New England Biolabs, Germany)

12.35 Efficient delivery of Cas9 and gRNA for in vitro use of CRISPR/Cas9 technology (NOT for ECM evaluation)
Guillaume Freund (Polyplus Transfection, France)

Close session and concluding remarks

12.50 Light lunch*

Session 4: Young investigators meeting and round table on genome editing
Chairs: Nicola Amodio (Catanzaro, Italy) - Cirino Botta (Catanzaro, Italy)

14.10 - 14.40 Selected oral presentation

14.50 Round table

Award Ceremony

(Max Partecipants: 160 - Deadline: 22 May 2017)

full programme 2017
Filename: full-programme-2017.pdf
Dimensione: 954 KB


Filename: abstract-form-3.pdf
Dimensione: 268 KB


Filename: aicc-registration-form-2.pdf
Dimensione: 464 KB


Filename: hotel-accomodation.pdf
Dimensione: 253 KB


Filename: locandina.pdf
Dimensione: 4 MB




Print Friendly, PDF & Email
Leveraging protein structure and mechanistic knowledge to better understand human diseases in the personalized-medicine era @ Aula E – Istituti Biologici
Dic 1@14:30–19:30


Dr. Francesco Raimondi
CellNetworks Excellenz Cluster
University of Heidelberg


I’m broadly interested in applying structural and integrative bioinformatics approaches to
characterize and combine heterogeneous experimental information, with a special focus on understanding signal transduction mechanisms in health and disease.
I will present the results of an ongoing collaborative project aimed at revealing, through
integrative modelling, the structure and function of LRRK2, a multi-domain protein with dual GTPase and Kinase activities, which represents the main cause of congenital Parkinson Disease. We have recently proposed the first model of the quaternary structure of this key enzyme, which is now illuminating on new potential ways to allosterically modulate its kinase activity.
I also employ multi-scale methods, spanning from 3D structures to biological pathways, to
interpret the functional consequences of protein variations and modifications from large-scale genomics and proteomics datasets. I will show recent applications of these approaches in cancer genomics, discussing their potential as predictive tools for personalized-medicine applications.


Massimo Donatelli: massimo.donatelli[et]

Daniele Dell'Orco: daniele.dellorco[et]

Print Friendly, PDF & Email
Mar 8 giorno intero
ORGANOID MODELS AND APPLICATIONS IN BIOMEDICAL RESEARCH @ Aula Magna “Giorgio De Sandre”, University of Verona | Verona | Veneto | Italia

Model systems drive biological research by recapitulating body processes and functions from the molecular to whole organism level. The human body is composed of both cellular and non-cellular material organized in a specialized manner. It is difficult to mimic all aspects of human biology with one in-vitro model. 3D cell culture models are a more accurate representation of the natural environment experienced by cells in the living organism as opposed to growing cells on 2D flat surfaces. In particular, organoids are in-vitro derived 3D cell aggregates derived from primary tissue or stem cells that are capable of self-renewal, self-organization and exhibit organ functionality. Organoids are physiologically relevant and amenable to molecular and cell biological analyses, holding great promise in both basic research and translational applications. The workshop is focused on the identification of organoid models of human diseases, as cancer and cystic fibrosis. The history of organoids and their future applications in the biomedical research is also discussed.

For information:

Filename: meeting-organoids-program-marzo2018.pdf
Dimensione: 432 KB
Payment Registration
Filename: payment-registration-2.doc
Dimensione: 165 KB

Print Friendly, PDF & Email
Liposomi e veicolazione di farmaci @ Istituto Superiore di Sanità
Mag 2 giorno intero


Nell'ambito delle attività dell'Istituto sono svolte numerose ricerche su sistemi cellulari in vitro, che prevedono l'utilizzo di sistemi, nanomerici per la veicolazione di farmaci in linee cellulari tumorali. L'approfondimento di sistemi non di sintesi e l'analisi critica della preparazione di vettori liposomiali adatti a veicolare in modo direzionale un farmaco di elezione per il fenotipo tumorale, è di sicura rilevanza per la sanità pubblica.


Scopo e obiettivi.

Il workshop si propone di informare ed aggiornare i partecipanti sulle possibilità applicative dei liposomi nel trasporto e direzionalità dei farmaci antitumorali.


Informazioni e domanda di iscrizione:


locandina workshop
Filename: locandina-workshop.doc
Dimensione: 334 KB

Domanda iscrizione AICC 2018
Filename: domanda-iscrizione-aicc-2018.doc
Dimensione: 119 KB

Print Friendly, PDF & Email